Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Article Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorAuthor: Jeffrey Neal Johnson. Originally Published: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of approximately $245 per share, creating a divergence that has caught Wall Street's attention. This rally undercuts the common perception of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed roughly 14%, significantly outperforming the broader market during a period of uncertainty. The price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and operational execution. For investors watching the ticker today, Feb. 24, 2026, note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely decline by the amount of the upcoming dividend payment, $1.30 per share. This is a mechanical market adjustment, not a reflection of business performance or a sell-off. For income-focused investors, this technical dip often represents an attractive entry point rather than a signal to exit. 64 Years of Unbroken Growth The main argument for holding Johnson & Johnson during turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings —companies that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has now raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes, and geopolitical conflicts. That reliability is a rare commodity in a market still fixated on speculative growth. Currently, the stock yields approximately 2.12%, based on an annual payout of $5.20 per share. While higher yields can be found in the bond market or riskier sectors, the appeal here is the combination of growth and safety. The dividend is supported by a massive liquidity cushion: management projects free cash flow to reach roughly $21 billion in 2026. This level of cash generation helps ensure the company can continue paying shareholders, invest in research, and manage legal expenses without heavy borrowing. For risk-averse investors, one of the most compelling metrics is the stock's beta. Beta measures how much a stock moves compared to the overall market (S&P 500). A beta of 1.0 means the stock moves in lockstep with the market. Johnson & Johnson currently has a beta of just 0.35, meaning the stock has historically been about 65% less volatile than the broader market. When tech stocks swing wildly, J&J tends to hold its ground. Adding JNJ to a portfolio heavy in technology acts as a mathematical shock absorber, dampening overall volatility while maintaining equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe stocks is that they do not grow. Johnson & Johnson is disproving that with a strategic pivot that is paying off. Management has issued strong guidance for 2026, projecting full-year revenue to cross the $100 billion threshold for the first time in the company's history. Alongside this revenue milestone, the company anticipates an adjusted earnings per share (EPS) of approximately $11.53. This growth is driven by a successful reinvention of its pharmaceutical division, now branded as Innovative Medicine. For years, investors worried about the patent cliff facing Stelara, a blockbuster immunology drug that lost exclusivity protection in 2025. Typically, when a top drug faces generic competition, revenue collapses. However, J&J has largely absorbed that decline through the meteoric rise of new blockbuster drugs. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse generates roughly $14 billion in annual sales. It has cemented the company's leadership in treating multiple myeloma and become a foundational therapy worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya recently reported strong three-year remission data for ulcerative colitis. Those clinical results are crucial because they demonstrate the company can retain market share in the competitive immunology space even as older drugs fade.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech (medical technology) division. This segment has shifted toward high-growth, high-margin technologies. A prime example is the integration of Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave uses intravascular lithotripsy (IVL) technology: sonic pressure waves break up calcified plaque in arteries, similar to treatment for kidney stones. This is a significant upgrade over traditional angioplasty balloons. By owning this technology, Johnson & Johnson secured a high-growth asset that complements its heart pump products and surgical businesses. Furthermore, the company is advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete in the rapidly expanding soft-tissue robotics market. These high-tech devices carry higher profit margins and create sticky relationships with hospital systems, providing a long-term earnings tailwind that goes beyond selling bandages or basic surgical tools. Addition by Subtraction: The Orthopedics Strategy To maintain growth and improve margins, management is actively reshaping the corporate structure. A major development is the potential separation of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a mega sale of the asset. Divesting the orthopedics unit represents an addition-by-subtraction strategy. Orthopedics is a mature, lower-growth business compared with booming fields like oncology and cardiovascular devices. By shedding this slower unit, Johnson & Johnson would improve its overall revenue growth rate and profit margins. A sale would also generate a significant lump-sum cash payment—potentially billions—providing additional capital for acquisitions or share buybacks. Addressing legal risks is essential for any balanced analysis. The company continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in the headlines. Additionally, a new commercial lawsuit from Bayer regarding marketing claims for prostate cancer drugs has added noise to the news cycle. However, the stock's recent rally suggests the market is looking past these headlines. The prevailing view among bulls is that Johnson & Johnson has the financial depth to manage these liabilities without disrupting its business. With over $20 billion in cash and marketable securities, the potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company has a financial fortress capable of absorbing legal settlements. That financial strength keeps legal battles a balance-sheet item rather than an existential threat to the dividend or operations. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. By shedding its consumer health division (Kenvue (NYSE: KVUE)) and potentially its orthopedics unit, management is streamlining operations to concentrate on higher-growth opportunities in pharmaceuticals and medical technology. While not a bargain-bin value play—trading near all-time highs—JNJ offers a premium blend of capital preservation and growth that is hard to find elsewhere. The combination of a 64-year dividend growth streak, a remarkably low volatility profile, and a clear path to $100 billion in revenue makes it a compelling option for 2026. For investors tired of the unpredictability in technology, Johnson & Johnson shows that, in the current market environment, boring can be both beautiful and profitable.
| 
